Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Effect of etomidate on adrenal function in rats.

R Hampl1, M Bicíková, K Motlík

  • 1Research Institute of Endocrinology, Praha, Czechoslovakia.

Endocrinologia Experimentalis
|September 1, 1987
PubMed
Summary

This study investigated how repeated exposure to the anesthetic etomidate affects adrenal gland structure and hormone production in rats. Researchers found that while high doses reduced specific hormone levels, lower doses actually increased production, suggesting the effects are reversible. The drug did not interfere with certain enzymatic pathways typically associated with adrenal blockers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitamin D in anxiety and affective disorders.

Physiological research·2015
Same author

Steroid hormones related to 11beta-hydroxysteroid dehydrogenase type 1 in treated obesity.

Physiological research·2015
Same author

Levels of adipokines and some steroids during the menstrual cycle.

Physiological research·2015
Same author

The role of steroid hormones in the development of intrahepatic cholestasis of pregnancy.

Physiological research·2015
Same author

Steroid hormones in the development of postpartum depression.

Physiological research·2014
Same author

Dehydroepiandrosterone, its metabolites and ion channels.

The Journal of steroid biochemistry and molecular biology·2014

Area of Science:

  • Endocrinology research involving etomidate impact on adrenal physiology
  • Pharmacology and toxicology studies within metabolic medicine

Background:

The precise impact of repeated anesthetic exposure on endocrine regulation remains poorly understood in rodent models. Prior research has shown that imidazole derivatives can influence steroidogenesis pathways within glandular tissues. That uncertainty drove this investigation into potential physiological alterations following prolonged drug administration. No prior work had resolved whether supra-therapeutic concentrations induce permanent morphological changes in adrenal cells. Existing literature often focuses on acute responses rather than the cumulative effects of repeated dosing regimens. This gap motivated a detailed assessment of hormonal output and tissue integrity in living subjects. Researchers sought to clarify if observed endocrine shifts correlate with structural modifications in the adrenal cortex. Establishing these relationships provides a clearer picture of how synthetic hypnotics interact with complex hormonal feedback loops.

Purpose Of The Study:

The study aimed to determine if repeated treatment with the imidazole-derived hypnotic alters adrenal morphology and function. Researchers sought to evaluate changes in corticosterone and 11-beta-hydroxyandrostenedione production within living subjects and isolated tissue samples. The investigation was motivated by the need to understand the endocrine consequences of doses exceeding standard human therapeutic levels. By testing both in vivo and in vitro, the team intended to clarify the direct versus systemic effects of the drug. The authors addressed the uncertainty surrounding whether prolonged exposure induces permanent glandular damage or functional impairment. This research provides a detailed look at the dose-response relationship of the hypnotic on adrenal steroidogenesis. The primary goal was to establish whether the drug acts as a blocker of specific adrenal enzymes. Understanding these interactions is essential for assessing the safety profile of the anesthetic in clinical practice.

Keywords:
steroidogenesiscorticosteroneimidazole derivativesendocrine toxicology

Frequently Asked Questions

The researchers propose that the hypnotic agent induces a dose-dependent reduction in corticosterone and 11-beta-hydroxyandrostenedione levels. While high concentrations suppress these hormones, lower doses unexpectedly trigger an increase in production, demonstrating a reversible physiological response to the drug.

The study utilized 11-beta-hydroxyandrostenedione as a specific androgenic marker. This compound is produced exclusively within the adrenal gland, allowing the investigators to isolate the impact of the drug on adrenal-specific steroidogenesis pathways compared to systemic hormonal fluctuations.

The authors state that the drug does not stimulate the enzymatic oxidation of 11-hydroxysteroids to 11-oxosteroids. This mechanism is distinct from other known blockers of 11-beta-hydroxylase, which typically interfere with this specific chemical conversion process.

Related Experiment Videos

Main Methods:

The review approach involved a systematic evaluation of repeated drug administration in a rodent model. Investigators applied the imidazole derivative at various concentrations to assess both in vivo and in vitro responses. The team measured plasma levels of corticosterone and 11-beta-hydroxyandrostenedione to quantify hormonal output changes. Researchers compared these results against control groups receiving no treatment to establish baseline physiological metrics. The study design incorporated doses exceeding standard human therapeutic levels to observe potential toxicological thresholds. Histological examination of the adrenal glands allowed for the identification of structural modifications like lipid accumulation. Statistical analysis determined the correlation between drug concentration and hormonal suppression or stimulation. This methodology ensured a comprehensive assessment of both functional and morphological impacts across different experimental conditions.

Main Results:

Key findings from the literature indicate that high concentrations of the drug significantly reduce plasma corticosterone and 11-beta-hydroxyandrostenedione levels. A dose-related decrease was observed starting at 0.3 mg/kg and 1.4 mg/kg for these respective hormones. In vitro experiments confirmed that corticosterone production dropped in groups receiving 0.7 mg or more. Low doses, approximately half of typical human levels, resulted in an increase in corticosterone production. Morphological analysis revealed only minor lipid hyperplasia after the highest dose administration. This structural change occurred alongside a significant increase in relative body weight among the subjects. The drug failed to stimulate the enzymatic oxidation of 11-hydroxysteroids to 11-oxosteroids. These results demonstrate that the agent does not act as a typical 11-beta-hydroxylase blocker.

Conclusions:

The authors propose that repeated exposure to this hypnotic agent alters adrenal hormone output in a dose-dependent manner. Synthesis and implications suggest that high concentrations suppress the production of specific steroids like corticosterone and androgenic precursors. The researchers note that lower doses appear to stimulate hormonal activity, highlighting the potential for reversible physiological responses. Evidence indicates that the drug does not function by inhibiting the oxidation of 11-hydroxysteroids. This finding distinguishes the agent from other known blockers of the 11-beta-hydroxylase enzyme. The study emphasizes that morphological changes, such as lipid hyperplasia, remain minimal even at the highest tested levels. These observations suggest that the endocrine system maintains a degree of functional plasticity despite pharmacological challenges. The findings offer a framework for understanding the safety profile of this anesthetic in long-term clinical applications.

Plasma concentrations served as the primary data type for evaluating systemic hormonal changes. These measurements allowed the team to correlate specific drug dosages with the resulting suppression or stimulation of adrenal output in the living subjects.

The researchers observed minimal lipid hyperplasia in the adrenal tissue. This structural change was only detected following the administration of the highest tested dose, indicating that significant morphological damage is not a primary outcome of this treatment.

The authors propose that the observed endocrine effects are reversible. This conclusion is supported by the finding that lower doses of the drug led to an increase in corticosterone production rather than the suppression seen at higher levels.